Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection
Launched by BAQIYATALLAH MEDICAL SCIENCES UNIVERSITY · Jun 30, 2008
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
Patients with Thalassemia receive chronic blood transfusions and have an increased prevalence of chronic Hepatitis C virus (HCV) infection, particularly if transfused before HCV serological testing became available. The investigators enrolled 300 patients into the study. The patients received PEGASYS (Peginterferon alpha-2a(40 KD)) 180 microgram per week plus COPEGUS (Ribavirin) 1000 milligram for weight less than or equal 75 kg and 1200 milligram for more than 75 kg for 48 weeks. Follow up period is 6 months after treatment. The patients are visited every 4 weeks with biochemistry lab test...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • HCV RNA positive
- • Age older than 12 years
- Exclusion Criteria:
- • Ongoing pregnancy or breast feeding
- • History (Hx) of Hepatocellular Carcinoma (HCC)
- • Hx of alcoholic liver disease
- • Hx of bleeding from esophageal varices
- • Hx of hemochromatosis
- • Hx of autoimmune hepatitis
- • Hx of Suicidal attempt
- • Hx of cerebrovascular dis
- • Hx of severe retinopathy
- • Hx of severe psoriasis
- • Hx of scleroderma
- • Hx of metabolic liver disease
- • Hx of Systemic Lupus Erythematosus (SLE)
About Baqiyatallah Medical Sciences University
Baqiyatallah Medical Sciences University is a distinguished institution dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, the university emphasizes the integration of scientific inquiry and clinical practice, fostering an environment that supports the development of new therapies and medical technologies. With a commitment to ethical standards and patient safety, Baqiyatallah Medical Sciences University collaborates with a network of healthcare professionals and researchers to address pressing medical challenges, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Trial Officials
Seyed-Moayed Alavian, Professor
Study Chair
Baqiyatallah Research Center for Gastroenterology and Liver Disea
Seyyed Mohammad Miri, M.D.
Study Director
Baqiyatallah Research Center for Gastroenterology and Liver Disea
Pegah Karimi, M.D.
Principal Investigator
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Maryam Keshvari, M.D.
Principal Investigator
Iranian blood Transfusion Research Center
Bita Behnava, M.D.
Principal Investigator
Baqiyatallah Research Center for Gastroenterology and Liver Diseases
Mohammad Hossein Somi, M.D.
Principal Investigator
Research Center for Gastroenterology and Hepatology, Tabriz University of Medical Sciences, Tabriz
Fariborz Mansour-Ghanaei, M.D.
Principal Investigator
Gastroenterology and Liver Diseases, Gastrointestinal and Liver Diseases Research Center (GLDRC), Guilan University of Medical Sciences, Rasht, Iran
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials